Drugs / Cetuximab β
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07714447 | Nov 2026 → Feb 2029 expected | colorectal cancer | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07503639 | Apr 2026 → Apr 2028 expected | colorectal cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07463677 | Mar 2026 → May 2028 expected | non-small cell lung carcinoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07446270 | Mar 2026 → Oct 2027 expected | colorectal cancer | Chinese PLA General Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07327411 | Dec 2025 → Feb 2027 expected | refractory malignant neoplasm | Second Affiliated Hospital of Soochow University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07198841 | Nov 2025 → Sep 2027 expected | non-small cell lung carcinoma | Guangdong Association of Clinical Trials | Recruiting | No outcome recorded |
| Phase 2 | NCT07059338 | Jul 2025 → Dec 2027 expected | HER2 positive breast carcinoma, colorectal cancer | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06959589 | May 2025 → May 2027 expected | metastatic malignant neoplasm in the colon | Second Affiliated Hospital, School of Medicine, Zhejiang University | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT07000305 | May 2025 → May 2027 expected | colorectal cancer | Tao Zhang | Not yet recruiting | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT07257653 Background | Oct 2025 → Dec 2026 expected | colorectal adenocarcinoma | Zhejiang University | Recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT07302841 Background | Jan 2026 → Jun 2027 expected | pancreatic neoplasm | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cetuximab β | “Drug3: anti-EGFR monoclonal antibody，cetuximab β 500mg/m2， d1， q3w， ≥8 cycles” NCT07327411 ↗10“Tunlametinib + Cetuximab β Injection” NCT07714447 ↗ |
| Action | Inhibit | “cetuximab beta (anti-EGFR)” NCT07059338 ↗ |
| Modality | Monoclonal antibody | “an EGFR monoclonal antibody” NCT07302841 ↗ |
| Route | Intravenous | “500 mg/m2 IV over 60- 120 min” NCT07000305 ↗ |
| Target | EGFR | “cetuximab beta (anti-EGFR)” NCT07059338 ↗ |